Clinical trial · Observational
Relationship Between Circulating Tumor Cell Cultures' Treatment Response and Clinical Outcomes
LCCC 1938: Investigating the Relationship Between Circulating Tumor Cell Cultures Treatment Response and Clinical Outcomes
NCT04280640CI-TRIAL-00054499withdrawnClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): PI left UNC.
Summary
Brief summary (as posted)
The purpose of this prospective, non-randomized, single-center pilot exploratory study is to investigate whether established circulating tumor cell (CTC) cultures have a similar response to targeted therapy treatment as the in vivo (patients') disease.
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Cancer | Malignant Bladder Neoplasm | CURATED_EXACT | 0.92 |
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Circulating Tumor Cell | — | UNRESOLVED | — |
| Gastrointestinal Cancer | Malignant Digestive System Neoplasm | ALIAS | 0.90 |
| Metastasis Lung | — | UNRESOLVED | — |
| Metastasis to Liver | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood Draw | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Metastatic Cancer Pts Receiving Molecularly Targeted Therapy
- description
- Metastatic cancer patients (with liver and/or lung metastasis) who will receive molecularly targeted therapy based on genomic testing data
- interventionNames
- Other: Blood Draw
- label
- GI Cancer Pts
- description
- Gastrointestinal cancer patients (with liver and/or lung metastasis) who will receive 3rd line treatments or enrolled on a targeted therapy treatment trial
- interventionNames
- Other: Blood Draw
- label
- Bladder Cancer Pts
- description
- Bladder cancer patients (with liver and/or lung metastasis) who will receive systemic treatment
- interventionNames
- Other: Blood Draw
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with a metastatic solid tumor malignancy with either liver and/or lung metastasis. Patients with newly diagnosed metastatic disease who have not had systemic therapy or are progressing on systemic therapy fitting one of the following cohorts: * Patients had a tumor or liquid biopsy with molecular analysis (genomic analysis or other type of molecular characterization) resulting in a therapeutic target with planned targeted therapy by the patient's treating physician. * Gastric cancer patients who have failed the first and second line chemotherapy. * Bladder cancer patients (with liver and/or lung metastasis) who will receive systemic treatment. * Scheduled to initiate systemic treatment for management of their disease. The systemic treatment will be either cytotoxic chemotherapy or targeted therapy but not checkpoint inhibitor immunotherapy. * ≥18 years of age * Written informed consent obtained and signed * Able to have blood collection without excessive difficulty Exclusion Criteria: * Patient unwilling or unable to complete informed consent * Currently pregnant or lactating women * Physical or psychological inability to complete sample collection for any reason including but not limited to: inability to tolerate any study procedures, any physical limitation that would undermine the safety of the subject in the study, or any psychiatric or neurological condition that inhibits full comprehension of study requirements and inability to complete informed consent, as determined by treating physician
References
Publications (0)
Data not yet available
No reference posted for this study.